Steven Isakoff

List of Publications by Year
in descending order

19	1,045	933447 10	888059 17
papers	citations	h-index	g-index

19	19	19	2343
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Convergent loss of PTEN leads to clinical resistance to a PI(3)KÎ± inhibitor. Nature, 2015, 518, 240-244.	27.8	486
2	Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence. Journal of Clinical Oncology, 2015, 33, 3621-3627.	1.6	172
3	Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. Journal of Clinical Oncology, 2021, 39, 2375-2385.	1.6	76
4	Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. Journal of Clinical Oncology, 2022, 40, 12-23.	1.6	75
5	Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer. Cancer Discovery, 2021, 11, 2436-2445.	9.4	69
6	Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, , 1-8.	4.9	36
7	Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. Breast Cancer Research and Treatment, 2015, 154, 287-297.	2.5	26
8	Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer. Npj Precision Oncology, 2019, 3, 18.	5.4	25
9	Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer. Clinical Cancer Research, 2022, 28, 993-1003.	7.0	21
10	Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer. JCO Precision Oncology, 2020, 4, 1246-1262.	3.0	16
11	RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer. Clinical Cancer Research, 2021, 27, 4883-4897.	7.0	11
12	Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer. Clinical Cancer Research, 2021, 27, 3404-3413.	7.0	10
13	Phase II Single-Arm Study to Assess Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2-Negative Tumors and HER2-Positive Circulating Tumor Cells. JCO Precision Oncology, 2021, 5, 896-903.	3.0	6
14	Secondary Use of Patient Tissue in Cancer Biobanks. Oncologist, 2019, 24, 1577-1583.	3.7	5
15	Pilot study to assess prolonged overnight fasting in breast cancer survivors (longfast). Breast Cancer Research and Treatment, 2022, , .	2.5	5
16	LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2017, 35, 1009-1009.	1.6	3
17	Breast Medical Oncologists' Perspectives of Telemedicine for Breast Cancer Care: A Survey Study. JCO Oncology Practice, 2022, 18, e1447-e1453.	2.9	3
18	Abstract PS18-19: Comparison of metastatic genomic profile in patients â‰45 years and patients >45 years with triple-negative breast cancer. , 2021, , .		0

#	Article	IF	Citations
19	Abstract P3-09-11: Clinical characteristics associated withBRCA1/2mutations identified on routine tumor tissue genotyping in metastatic breast cancer. Cancer Research, 2022, 82, P3-09-11-P3-09-11.	0.9	0